Home

Marker IDs Injury in Hypoxic-Ischemic Encephalopathy

17.10.11

MONDAY, Oct. 17 (HealthDay Scandal) -- Neonates with hypoxic-ischemic encephalopathy (HIE) treated with whole-council cooling have increased serum glial fibrillary acidic protein (GFAP) during the first week of mortal, which may be predictive of brain injury on magnetic resonance imaging (MRI), according to a about published in the September issue of the American Journal of Obstetrics & Gynecology .

Christopher S. Ennen, M.D., from the Johns Hopkins University Indoctrinate of Medicine in Baltimore, and colleagues investigated whether serum GFAP was increased in neonates with HIE treated with whole-firmness cooling. GFAP was measured at birth and daily for up to seven days. Neonates with HIE treated with whole-main part cooling were compared with neonates with HIE by brain abnormalities on MRI, and with gestational age-matched controls without neurological mistreatment.

Source: Doctors Lounge

Serum N-Acetylaspartate Level Potential Biomarker in ALS

14.10.11

THURSDAY, Oct. 13 (HealthDay Gossip) -- The level of serum N -acetylaspartate (NAA) is significantly higher in patients with amyotrophic lateral sclerosis (ALS) than shape individuals, according to a study published in the October big problem of the Archives of Neurology .

Isabella L. Simone, M.D., from the University of Bari in Italy, and colleagues investigated whether serum NAA levels could be acclimated to as a possible biomarker of ALS in 112 patients with ALS and 51 age- and gender-matched wholesome controls. Serum NAA was assayed by liquid chromatography-mass spectrometry. The associations between the serum NAA knock down and clinical variables in patients were measured using mongrel estimating equations.

The investigators found that there was a significantly higher serum NAA consistent in patients with ALS than in controls. The serum NAA level was directly associated with the composure of ALS in multivariate logistic regression analysis. The age- and gender-matched odds proportion for ALS was 19.97, after stratifying the serum NAA level by the median value (0.171 mmol/L). No differences were observed in the NAA flat across ALS clinical phenotypes, and riluzole treatment had no effect on the NAA even. The serum NAA level was significantly correlated with the rate of ALS progression.

Source: Doctors Lounge

Skin Authority Brightening Serum- reviewed and rejected

16.10.11

The other day, I described Hide Authority as a Dr Jekyll and Mr Hyde company with some of its formulations being rather foetid, while others were apparently benign. I had bought Skin Authority’s Brightening Serum, judging that the sensitive Dr Jekyll had had more of a hand in it then his murderous alter ego. My assumption, I discovered thanks to Theresa, proved to be iniquitous and, in Breast Cancer Awareness Month, ironically so.

My alcoholic drink of Skin Authority’s Brightening Serum lists BHA as an ingredient. I took this to be beta-hydroxy acid, an exfoliant that would be contributing to the pelt lightening. Dark spot fading properties of this serum.  But then Theresa formerly larboard a comment on my post saying that BHA was much more likely to be the preservative butylated hydroxyanisole. I ought to be appreciative to her, even though she seriously rained on my parade.

Butylated hydroxyanisole and its detailed relative, butylated hydroxytoulene (BHT) are very controversial ingredients. As pioneer as 1995, Business Week reported: “Repeated studies have shown that BHA and BHT snowball the risk of cancer as well as accumulate in body tissue, occasion liver enlargement, and retard the rate of DNA synthesis and thus, cubicle development.”

Source: Truth In Aging